PSP Research LLC holds a concentrated book of 75 stocks worth $187.9M as of Q2 2026 (disclosed Jul 9, 2026, a ~9-day 13F lag). This quarter they opened Ascendis Pharma A/s and trimmed Nurix Therapeutics Inc. Their largest long position is SS SPDR S&P Biotech ETF at 48% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
14% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as PSP Research LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 79 / 75 | $33.8B |
| MORGAN STANLEY | 79 / 75 | $9.1B |
| GOLDMAN SACHS GROUP INC | 79 / 75 | $6.1B |
| JPMORGAN CHASE & CO | 79 / 75 | $5.5B |
| UBS Group AG | 79 / 75 | $4.4B |
| BARCLAYS PLC | 79 / 75 | $853.0M |
| FMR LLC | 78 / 75 | $27.4B |
| BANK OF AMERICA CORP /DE/ | 78 / 75 | $6.9B |
Ranked by the share of each fund's own book sitting in the names it shares with PSP Research LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | SPDR Series Trust ST STR SP BIOT | $90.2M | 570.0K | 48.0% | ▲+100% Added · +285K sh | |
| 2 | Ishares TR 0-3 MTH TREASURY | $70.5M | 700.0K | 37.5% | —Held | |
| 3 | Royalty Pharma PLC SHS CLASS A | $617K | 11.0K | 0.3% | —Held | |
| 4 | Nurix Therapeutics Inc COM | $607K | 25.0K | 0.3% | ▼−13% Reduced · −4K sh | |
| 5 | Incyte Corp COM | $601K | 5.3K | 0.3% | —Held | |
| 6 | Argenx SE SPONSORED ADR | $595K | 641 | 0.3% | —Held | |
| 7 | Disc Medicine Inc COM | $585K | 8.0K | 0.3% | —Held | |
| 8 | Rapport Therapeutics Inc COM | $583K | 14.0K | 0.3% | —Held | |
| 9 | Ultragenyx Pharmaceutical In COM | $568K | 17.0K | 0.3% | ▼−23% Reduced · −5K sh | |
| 10 | Trevi Therapeutics Inc COM | $560K | 30.0K | 0.3% | —Held | |
| 11 | Monte Rosa Therapeutics Inc COM | $557K | 23.0K | 0.3% | ▼−18% Reduced · −5K sh | |
| 12 | TG Therapeutics Inc COM | $549K | 10.0K | 0.3% | ▼−23% Reduced · −3K sh | |
| 13 | Halozyme Therapeutics Inc COM | $548K | 7.0K | 0.3% | ▼−13% Reduced · −1K sh | |
| 14 | Ionis Pharmaceuticals Inc COM | $539K | 6.8K | 0.3% | —Held | |
| 15 | Pharvaris N V COM | $519K | 15.0K | 0.3% | ▼−25% Reduced · −5K sh | |
| 16 | Arcutis Biotherapeutics Inc COM | $517K | 19.7K | 0.3% | —Held | |
| 17 | Aurinia Pharmaceuticals Inc COM | $509K | 30.0K | 0.3% | —Held | |
| 18 | Neurocrine Biosciences Inc COM | $506K | 3.0K | 0.3% | ▼−22% Reduced · −848 sh | |
| 19 | Immunovant Inc COM | $501K | 13.0K | 0.3% | ▼−32% Reduced · −6K sh | |
| 20 | Acadia Pharmaceuticals Inc COM | $500K | 19.8K | 0.3% | —Held | |
| 21 | PTC Therapeutics Inc COM | $489K | 6.0K | 0.3% | —Held | |
| 22 | Celldex Therapeutics Inc New COM NEW | $484K | 13.0K | 0.3% | —Held | |
| 23 | Immunocore Hldgs PLC ADS | $481K | 15.1K | 0.3% | —Held | |
| 24 | Definium Therapeutics Inc COM SHS | $470K | 10.0K | 0.3% | ▼−71% Reduced · −25K sh | |
| 25 | Cogent Biosciences Inc COM | $464K | 12.0K | 0.2% | —Held | |
| 26 | Kymera Therapeutics Inc COM | $459K | 4.0K | 0.2% | ▼−37% Reduced · −2K sh | |
| 27 | Dyne Therapeutics Inc COM | $444K | 20.0K | 0.2% | —Held | |
| 28 | Alnylam Pharmaceuticals Inc COM | $441K | 1.5K | 0.2% | —Held | |
| 29 | Tarsus Pharmaceuticals Inc COM | $441K | 7.0K | 0.2% | —Held | |
| 30 | Syndax Pharmaceuticals Inc COM | $437K | 20.0K | 0.2% | —Held | |
| 31 | Exelixis Inc COM | $435K | 8.0K | 0.2% | ▼−33% Reduced · −4K sh | |
| 32 | Crinetics Pharmaceuticals In COM | $412K | 11.0K | 0.2% | —Held | |
| 33 | Newamsterdam Pharma Company ORDINARY SHARES | $407K | 12.0K | 0.2% | ▼−20% Reduced · −3K sh | |
| 34 | Ascendis Pharma A/s ORD SHS | $400K | 1.5K | 0.2% | ▲New New position | |
| 35 | Liquidia Corporation COM NEW | $399K | 5.0K | 0.2% | ▲New New position | |
| 36 | Stoke Therapeutics Inc COM | $393K | 12.0K | 0.2% | —Held | |
| 37 | Viking Therapeutics Inc COM | $390K | 10.0K | 0.2% | ▼−33% Reduced · −5K sh | |
| 38 | Immunome Inc COM | $381K | 18.0K | 0.2% | ▼−10% Reduced · −2K sh | |
| 39 | Protagonist Therapeutics Inc COM | $368K | 3.0K | 0.2% | —Held | |
| 40 | Harmony Biosciences Hldgs In COM | $364K | 10.0K | 0.2% | ▼−30% Reduced · −4K sh | |
| 41 | Enliven Therapeutics Inc COM | $355K | 7.0K | 0.2% | —Held | |
| 42 | Spyre Therapeutics Inc COM NEW | $355K | 4.0K | 0.2% | ▼−22% Reduced · −1K sh | |
| 43 | Intellia Therapeutics Inc COM | $338K | 20.0K | 0.2% | ▼−26% Reduced · −7K sh | |
| 44 | Madrigal Pharmaceuticals Inc COM | $322K | 600 | 0.2% | —Held | |
| 45 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $320K | 5.0K | 0.2% | ▼−44% Reduced · −4K sh | |
| 46 | Alkermes PLC SHS | $314K | 6.0K | 0.2% | —Held | |
| 47 | Tango Therapeutics Inc COM | $313K | 10.0K | 0.2% | ▼−31% Reduced · −4K sh | |
| 48 | Ardelyx Inc COM | $306K | 60.0K | 0.2% | ▼−25% Reduced · −20K sh | |
| 49 | Vera Therapeutics Inc CL A | $300K | 7.0K | 0.2% | ▼−30% Reduced · −3K sh | |
| 50 | Mirum Pharmaceuticals Inc COM | $293K | 2.5K | 0.2% | ▼−50% Reduced · −3K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2106939/holdings"
Use Arkolith to show PSP Research LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.